TY - JOUR
T1 - Utility of mammography for chronic kidney disease patients undergoing kidney transplant evaluation
AU - Stoecker, Jordan B.
AU - Cote, Devan R.
AU - Augustine, Joshua J.
AU - Sarabu, Nagaraju
AU - Schulak, James A.
AU - Sanchez, Edmund Q.
AU - Humphreville, Vanessa R.
AU - Ammori, John B.
AU - Woodside, Kenneth J.
N1 - Publisher Copyright:
© 2016 John Wiley & Sons A/S.
PY - 2016/4/1
Y1 - 2016/4/1
N2 - Transplant centers typically require screening mammography (MMG) for women ≥40 during evaluation. American Cancer Society recommends starting annual MMG at 40, while USPSTF recommends biennial MMG at 50. We sought to determine the effect of age and other breast malignancy risk factors on screening MMG in the pre-transplant renal failure population undergoing transplant evaluation. Methods: We retrospectively examined women ≥40 undergoing kidney transplant evaluation from 2006 to 2012 (n = 541). Results: Patients aged 40.0-49.9 and ≥50 had similar rates of breast biopsy and breast malignancy. African Americans underwent a higher rate of biopsies (OR 2.391, 95%CI 1.111-5.019, p = 0.026), with a lower rate of biopsy in those already on dialysis at presentation (OR 0.434, 95%CI 0.212-0.888, p = 0.022). Higher breast density (>50% fibroglandular tissue) increased both rate of biopsy (OR 2.876, 95%CI 1.377-6.010, p = 0.005) and malignancy (OR 5.061, 95%CI 1.012-25.315, p = 0.048). Conclusions: As we found no independent differences in biopsy or malignancy between age groups, it is reasonable for transplant centers to use the same evaluation MMG screening policy for all women ≥40. However, as malignancy risk increased with higher breast density, a lower threshold for additional workup may be warranted in patients with dense breasts or an indeterminate lesion on MMG.
AB - Transplant centers typically require screening mammography (MMG) for women ≥40 during evaluation. American Cancer Society recommends starting annual MMG at 40, while USPSTF recommends biennial MMG at 50. We sought to determine the effect of age and other breast malignancy risk factors on screening MMG in the pre-transplant renal failure population undergoing transplant evaluation. Methods: We retrospectively examined women ≥40 undergoing kidney transplant evaluation from 2006 to 2012 (n = 541). Results: Patients aged 40.0-49.9 and ≥50 had similar rates of breast biopsy and breast malignancy. African Americans underwent a higher rate of biopsies (OR 2.391, 95%CI 1.111-5.019, p = 0.026), with a lower rate of biopsy in those already on dialysis at presentation (OR 0.434, 95%CI 0.212-0.888, p = 0.022). Higher breast density (>50% fibroglandular tissue) increased both rate of biopsy (OR 2.876, 95%CI 1.377-6.010, p = 0.005) and malignancy (OR 5.061, 95%CI 1.012-25.315, p = 0.048). Conclusions: As we found no independent differences in biopsy or malignancy between age groups, it is reasonable for transplant centers to use the same evaluation MMG screening policy for all women ≥40. However, as malignancy risk increased with higher breast density, a lower threshold for additional workup may be warranted in patients with dense breasts or an indeterminate lesion on MMG.
KW - Breast cancer
KW - Cancer screening
KW - Chronic kidney disease
KW - End-stage renal disease
KW - Kidney transplantation
KW - Mammography
UR - http://www.scopus.com/inward/record.url?scp=84959506942&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84959506942&partnerID=8YFLogxK
U2 - 10.1111/ctr.12709
DO - 10.1111/ctr.12709
M3 - Article
C2 - 26855387
AN - SCOPUS:84959506942
SN - 0902-0063
VL - 30
SP - 445
EP - 451
JO - Clinical Transplantation
JF - Clinical Transplantation
IS - 4
ER -